<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29346" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Spinal Muscle Atrophy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Burr</surname>
            <given-names>Pierce</given-names>
          </name>
          <aff>Greater Glasgow and Clyde</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Reddivari</surname>
            <given-names>Anil Kumar Reddy</given-names>
          </name>
          <aff>University of Illinois</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pierce Burr declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anil Kumar Reddy Reddivari declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29346.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Spinal muscular atrophy is an inherited autosomal recessive disease of a varying phenotype that is characterized by progressive muscle weakness, reduced tone with associated destruction of alpha motor units. There are four main subtypes of spinal muscular atrophy defined by the age of onset and severity with type 0 presenting in utero and causing death within the first months of life and type 4 in adulthood, causing mild weakness and no effect on lifespan. Understanding the underlying pathophysiology, subtypes, and emerging treatments is key to treating patients with spinal muscular atrophy effectively. This activity reviews the evaluation and treatment of spinal muscular atrophy and highlights the role of the interprofessional team in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Summarize the etiology of spinal muscular atrophy.</p></list-item><list-item><p>Describe the clinical subtypes seen in spinal muscular atrophy.</p></list-item><list-item><p>Outline the management options available for spinal muscular atrophy.</p></list-item><list-item><p>Summarize the importance of collaboration and communication amongst the interprofessional team to improve outcomes for patients affected by spinal muscular atrophy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29346&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29346">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29346.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Spinal muscular atrophy (SMA) denotes a collection of inherited clinical syndromes causing degeneration of anterior horn cells in the spinal cord with associated&#x000a0;destruction of alpha motor cells and presents clinically with characteristic proximal muscle weakness and atrophy.<xref ref-type="bibr" rid="article-29346.r1">[1]</xref> Homozygous deletion at 5q13 (the coding region for the survival motor neuron (SMN1) gene) is responsible for 95% of cases of SMA, and after cystic fibrosis is the second most common cause of autosomal recessive inherited related mortality with an estimated incidence of 1 in 6000&#x000a0;to 11000.<xref ref-type="bibr" rid="article-29346.r2">[2]</xref><xref ref-type="bibr" rid="article-29346.r3">[3]</xref></p>
        <p>Homozygous deletion at 5q13 is also referred to as classical proximal SMA and will be the focus of this article with differentials and other causes of SMA discussed below. SMA is heterogeneous in presentation and ranges from death within weeks of birth to mild proximal weakness developing during adulthood. Earlier presentations are typically associated with poorer function and prognosis: classification of SMA subtypes are determined by the age of onset as well as clinical severity and life expectancy.<xref ref-type="bibr" rid="article-29346.r4">[4]</xref>&#x000a0;</p>
        <p>SMA was first described in the 1890s, first by Guido Werdnig in describing intermediate and severe SMA in 2 brothers and then 7 cases by Johan Hoffmann; type I SMA is sometimes eponymously referred to as Werdnig-Hoffmann disease. Similarly, milder forms of SMA (type III) detailed by Kugelberg and Welander is sometimes eponymously referred to as Kugelberg-Welander disease.<xref ref-type="bibr" rid="article-29346.r5">[5]</xref></p>
      </sec>
      <sec id="article-29346.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>In 95% of cases, SMA results from a homozygous deletion of SMN1 on chromosome 5q13; however, this does not explain&#x000a0;how there can be significant clinical heterogeneity in phenotype.<xref ref-type="bibr" rid="article-29346.r6">[6]</xref> The answer lies in there being two versions of SMN: 1) telemoeric version (SMN1) 2) centromeric version (SMN2) with individuals varying in the number of copies of SMN2 they possess.<xref ref-type="bibr" rid="article-29346.r7">[7]</xref> SMN1 transcription produces a functionally complete mRNA, that can then be encoded to create the SMN protein. SMN2 transcription results in functionally complete mRNA 10&#x000a0;to 15% of the time, resulting in far fewer SMN protein being encoded than SMN1.<xref ref-type="bibr" rid="article-29346.r1">[1]</xref>&#x000a0;</p>
        <p>SMN2 is identical to SMN1 except for a single C-T substitution in exon 7. This substitution promotes splicing 80&#x000a0;to 85% of the time during transcription and resultant removal of exon 7.<xref ref-type="bibr" rid="article-29346.r1">[1]</xref>&#x000a0;This truncated mRNA causes similarly truncated non-functional proteins. Patients with SMA are lacking SMN1 and are therefore dependent on residual SMN2 production of functional SMN protein for alpha motor neuron function and subsequent survival.<xref ref-type="bibr" rid="article-29346.r8">[8]</xref> There is, therefore, a positive correlation seen between the number of copies of SMN2 and phenotype severity with SMA type 1 typically having 1&#x000a0;to 2 copies of SMN2 and SMA type 4 having 3&#x000a0;to 5 SMN2 copies.<xref ref-type="bibr" rid="article-29346.r8">[8]</xref></p>
        <p>There is not a perfect correlation as there are&#x000a0;anomalies in&#x000a0;phenotypic variation in SMN2, leading to varying amounts of functional SMN protein production in different individuals. Therefore a low number of SMN2 copies with a milder clinical phenotype have been described.<xref ref-type="bibr" rid="article-29346.r9">[9]</xref></p>
      </sec>
      <sec id="article-29346.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>SMA incidence has been estimated at 1&#x000a0;in 6000&#x000a0;to 11000, with a carrier frequency in the of mutations in SMN1 of 2&#x000a0;to 3% (1&#x000a0;in 40) in the general population.<xref ref-type="bibr" rid="article-29346.r10">[10]</xref><xref ref-type="bibr" rid="article-29346.r2">[2]</xref> Incidence varies according to&#x000a0;ethnicity, with the incidence reported as 8/100,000 for people of white ethnicity when compared with 0.89&#x000a0;in 100,000 for black ethnicity and 0.96/100,000 for those of mixed ethnicity.<xref ref-type="bibr" rid="article-29346.r11">[11]</xref>&#x000a0;Extrapolating from carrier frequency in the general population, one should expect a higher incidence of live births with SMA, one hypothesis is that fetuses&#x000a0;possessing 0 copies of SMN1+SMN2 fail to develop as is seen in other species with this genotype.<xref ref-type="bibr" rid="article-29346.r12">[12]</xref></p>
      </sec>
      <sec id="article-29346.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The precise role SMN protein plays in neuronal function and development is not fully understood, and its subsequent absence causing such devastating deficits has so far eluded precise pathophysiological descriptions. SMN protein is found in all eukaryotic cells and has shown to play a crucial role in all cells with regards to homeostatic cellular pathways.<xref ref-type="bibr" rid="article-29346.r13">[13]</xref>&#x000a0;</p>
        <p>Several hypotheses surrounding SMN protein and its role in SMA exist, two main hypotheses relate to SMN protein&#x02019;s role in 1) The neuronal cytoplasm and 2) the neuronal nucleus. SMN protein in the cytoplasm has demonstrated a vital role in mRNA transport through axons, actin dynamics, and vesicle release in the synapse. In the nucleus, SMN protein forms small nuclear RNA&#x02019;s (snRNA) and therefore plays a key role in the formation of the spliceosome, which removes introns in pre- mRNA into functional mRNA.<xref ref-type="bibr" rid="article-29346.r14">[14]</xref><xref ref-type="bibr" rid="article-29346.r3">[3]</xref></p>
        <p>This explanation hypothesizes the damage motor neurons specifically to either neuronal sensitivity to spliceosome malfunction directly or indirectly through incorrectly spliced mRNA creating dysfunctional proteins key to neuronal function.<xref ref-type="bibr" rid="article-29346.r3">[3]</xref><xref ref-type="bibr" rid="article-29346.r15">[15]</xref>&#x000a0;Recent developments in the understanding of SMN protein regarding its ubiquitous presence and multiple functions in all eukaryotic cells have led to conclusions that SMA is not purely a motor neuron disorder with congenital heart disorder associations and sensory nerve pathology noted in type 1 SMA patients.<xref ref-type="bibr" rid="article-29346.r16">[16]</xref><xref ref-type="bibr" rid="article-29346.r17">[17]</xref></p>
      </sec>
      <sec id="article-29346.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The natural history and examination findings in SMA are dependent on phenotypic variation and are classified clinically into SMA &#x02018;types&#x02019;.<xref ref-type="bibr" rid="article-29346.r18">[18]</xref> In all SMA types, notably, cognition is not affected, and patients reportedly have average to above-average intelligence.<xref ref-type="bibr" rid="article-29346.r19">[19]</xref>&#x000a0;Below outlines the four main types of SMA:</p>
        <list list-type="bullet">
          <list-item>
            <p>Type 0 (aka type 1a, congenital SMA)- Present in the neonatal period with hypotonia, early respiratory failure, severe weakness, and typically decreased fetal movements with associated arthrogryposis. Death usually occurs at birth or within the first month of life; this is a rare phenotype.<xref ref-type="bibr" rid="article-29346.r20">[20]</xref><xref ref-type="bibr" rid="article-29346.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Type I (aka Werdnig-Hoffman disease, &#x02018;non-sitters,&#x02019; severe SMA) - Present in the first six months of life with limited head control, hypotonia and areflexia. Type I is defined as &#x02018;non-sitters&#x02019; with a frog-like posture when supine. The weakness of intercostal muscles and preserved diaphragmatic function leads to a paradoxical breathing pattern and a bell-shaped chest. Swallowing difficulties are a typical feature with tongue fasciculations and associated complications such as failure to thrive and aspiration. Other cranial nerves are not normally affected at presentation, but facial nerve weakness typically develops later in the course of the disease. Notably, cognition is not affected, and patients are often described as alert and bright when diagnosed. Without ventilatory support, most succumb to the disease before two years of age. Type I is sometimes further divided into IA (or type 0, see above), IB: onset &#x0003c;3 months, IC: onset 3-6 months.<xref ref-type="bibr" rid="article-29346.r4">[4]</xref><xref ref-type="bibr" rid="article-29346.r15">[15]</xref><xref ref-type="bibr" rid="article-29346.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p>Type II (aka Dubowitz disease, &#x02018;sitters,&#x02019; intermediate SMA) - Presents at 6 to 18 months old; able to sit but with hypotonia, areflexia, a progressive proximal weakness that disproportionately affects the legs over arms. Progressive scoliosis and intercostal muscle weakness result in restrictive lung disease. Other notable characteristics are polyminimyoclonus of the hands, ankylosis of the mandible, and joint contractures. Around 70% of patients will survive until 25, with some surviving into the third decade; respiratory compromise is the major cause of mortality.<xref ref-type="bibr" rid="article-29346.r4">[4]</xref><xref ref-type="bibr" rid="article-29346.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Type III (aka Kugelberg-Welander disease, &#x02018;walkers,&#x02019; mild SMA) - Presents after 18 months similarly to type II with progressive proximal weakness disproportionately affecting legs over arms, however, patients are ambulatory but can require a wheelchair as the disease progresses. Patients do not typically suffer from restrictive lung disease, and life expectancy is not affected. Type III sometimes further subdivides into IIIA: presents 18 months-3 years and IIIB: presents &#x0003e;3 years.<xref ref-type="bibr" rid="article-29346.r4">[4]</xref><xref ref-type="bibr" rid="article-29346.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Type IV (aka adult SMA) - Patients present in adulthood (&#x0003e;21 years old) and is the mildest phenotype of SMA. Patients are ambulatory and present with mild leg weakness and develop progressive proximal weakness. Life expectancy is not typically affected.<xref ref-type="bibr" rid="article-29346.r23">[23]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29346.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>If a clinician clinically suspects SMA following a thorough history and clinical exam, genetic testing is usually sufficient to confirm a diagnosis of SMA.<xref ref-type="bibr" rid="article-29346.r21">[21]</xref> Polymerase chain reaction (PCR) or multiplex ligation probe amplification (MLPA) can help to detect homozygous exon 7 deletion in the SMN1 gene.<xref ref-type="bibr" rid="article-29346.r24">[24]</xref> This test has 95% sensitivity and almost 100% specificity. Around 5% of individuals with SMA are heterogeneous and have one allele exon 7 deletion in SMN1 and another allele with an atypical point mutation. SMN2 detection is often performed at the same time to give an added prognostic indicator with higher SMN2 copies associated with less severe phenotypes.<xref ref-type="bibr" rid="article-29346.r25">[25]</xref></p>
        <p>Other diagnostic tests are options if initial genetic testing fails to detect homozygous SMN1 gene exon 7 deletion:</p>
        <list list-type="bullet">
          <list-item>
            <p>Creatinine kinase - normal (although can be very mildly elevated)&#x000a0;<xref ref-type="bibr" rid="article-29346.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Nerve conduction studies- sensory nerves demonstrate normal action potentials, motor nerves may show diminished motor action potentials&#x000a0;<xref ref-type="bibr" rid="article-29346.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Needle electromyography (EMG) - SMA type I: denervation changes without reinnervation. SMA II+III: Neurogenic patterns (action potentials with prolonged duration, increased amplitude, and diminished recruitment)&#x000a0;<xref ref-type="bibr" rid="article-29346.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Muscle biopsy - mostly obsolete as a diagnostic tool due to advances in genetic and less invasive testing but when performed in a patient with SMA shows a neurogenic pattern&#x000a0;<xref ref-type="bibr" rid="article-29346.r25">[25]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29346.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Historically there have been no disease-modifying treatments for SMA, and treatment has largely been supportive with early involvement of pediatric palliative care specialists, especially for types 0, I, and II.<xref ref-type="bibr" rid="article-29346.r15">[15]</xref> Novel therapies have recently been developed that are showing considerable promise in combating the extremely poor morbidity and mortality associated with SMA I and II.<xref ref-type="bibr" rid="article-29346.r9">[9]</xref></p>
        <p>Pulmonary - restrictive lung disease seen in type 0, I, and II causes respiratory failure and is ultimately the cause of death. Non-invasive ventilation, usually in the form of BiPAP (bilevel positive airway pressure), has been used as a way of increasing quality of life and life expectancy.<xref ref-type="bibr" rid="article-29346.r26">[26]</xref><xref ref-type="bibr" rid="article-29346.r27">[27]</xref>&#x000a0;Patients requiring this form of support will also have a weak cough and have an increased risk of respiratory compromise in the form of mucus plugging, aspiration, recurrent infections, and subsequent hypoxemia.<xref ref-type="bibr" rid="article-29346.r26">[26]</xref> The involvement of chest physiotherapists is key for cough assessments, mucous clearing, and tracking of forced vital capacity in children &#x0003e;5 years of age.<xref ref-type="bibr" rid="article-29346.r27">[27]</xref>&#x000a0;Where non-invasive ventilation is no longer sufficient difficult discussions regarding tracheostomy and permanent invasive ventilation need to be made, this should take place in a multi-disciplinary setting with early involvement of palliative care specialists.<xref ref-type="bibr" rid="article-29346.r26">[26]</xref></p>
        <p>Gastrointestinal - Due to associated muscle weakness, patients are prone to tire quickly and have swallowing difficulties&#x000a0;that can lead to a failure to thrive and have a negative compounding effect on muscle weakness. Other gastrointestinal symptoms include constipation, delayed gastric emptying, and reflux.<xref ref-type="bibr" rid="article-29346.r15">[15]</xref>&#x000a0;For patients with type I SMA early consideration of laparoscopic gastrostomy and Nissen fundoplication is important and can improve nutritional status and decrease the frequency of aspiration.<xref ref-type="bibr" rid="article-29346.r28">[28]</xref>&#x000a0;Patients with type II require close attention to nutritional status as although they may plot as being in the normal range on a growth chart for their age, they are more likely to have increased adiposity, the involvement of nutritionists is therefore vital in ensuring optimal nutritional management.<xref ref-type="bibr" rid="article-29346.r29">[29]</xref><xref ref-type="bibr" rid="article-29346.r30">[30]</xref>&#x000a0;</p>
        <p>Orthopedic - Patients suffer from orthopedic complications such as scoliosis, hip subluxation, and susceptibility to fractures. Type I and II are particularly affected by these complications, with type III being variably affected.<xref ref-type="bibr" rid="article-29346.r31">[31]</xref>&#x000a0;Physiotherapy involvement is important in optimizing and preserving function, and mobility with the use of stretching exercises and passive movement of joints helps to avoid joint contractures.<xref ref-type="bibr" rid="article-29346.r31">[31]</xref>&#x000a0;Similarly, orthotic specialist involvement is important to utilize frames, orthotics, and wheelchairs to improve quality of life and mobility. Orthopedic surgical monitoring is required for scoliosis with periodic&#x000a0;consideration for spinal fusion and bracing.<xref ref-type="bibr" rid="article-29346.r31">[31]</xref><xref ref-type="bibr" rid="article-29346.r15">[15]</xref></p>
        <p>Novel therapies - Traditionally, there has been no disease altering agents, and management has focused on optimizing the various clinical manifestations of SMA. Due to advances in understanding the underlying pathophysiology and breakthroughs in genetic therapeutics, there are now several promising novel agents that have shown to improve life span and decrease morbidity.<xref ref-type="bibr" rid="article-29346.r9">[9]</xref>&#x000a0;</p>
        <p>Nusinersen - Is an intrathecally delivered antisense oligonucleotide (ASO) that promotes functional SMN2 production by inhibiting ISS-N1 (an SMN2 exon 7 splicer) and thereby increasing the amount of functional SMN protein produced.<xref ref-type="bibr" rid="article-29346.r32">[32]</xref>&#x000a0;ENDEAR - a phase III clinical trial assessing Nusinersen effectiveness in SMA type I patients (with 2 SMN2 copies showed 51% achievement of motor milestones compared to 0% in the placebo group.<xref ref-type="bibr" rid="article-29346.r33">[33]</xref> Motor improvements also occurred in type II and III patients.<xref ref-type="bibr" rid="article-29346.r32">[32]</xref>&#x000a0;Nusinersen has received approval for use in the USA, Europe, Japan, Australia, for example. It costs $118,000 for one vial and&#x000a0;costs $708,000 for the first year of treatment.<xref ref-type="bibr" rid="article-29346.r34">[34]</xref><xref ref-type="bibr" rid="article-29346.r9">[9]</xref></p>
        <p>Onasemnogene abeparvovec - This onetime intravenous injection gene therapy utilizes the properties of adeno-associated virus serotype 9 and uses it to deliver the SMN1 gene into cells and thereby allowing the body to produce functioning SMN protein.<xref ref-type="bibr" rid="article-29346.r35">[35]</xref> A phase I/II study testing safety and efficacy of&#x000a0;onasemnogene abeparvovec in 15 patients with SMA I showed all patients were alive at 20 months compared to an expected 8% in historical cohorts. Furthermore, significant motor improvements were seen, with 11/15 able to sit unassisted in a cohort of patients classically defined by their inability to sit.<xref ref-type="bibr" rid="article-29346.r35">[35]</xref>&#x000a0;Onasemnogene abeparvovec is priced at $2.125 million for a single injection and has been reported to be the most expensive drug in the world.<xref ref-type="bibr" rid="article-29346.r36">[36]</xref> Onasemnogene abeparvovec is currently licensed for use in the USA.<xref ref-type="bibr" rid="article-29346.r34">[34]</xref><xref ref-type="bibr" rid="article-29346.r37">[37]</xref></p>
        <p>Risdiplam - This drug is an oral medication that works via modifying SMN2 splicing and thereby increasing functional SMN protein levels. There have been numerous phase II/III trials that have shown efficacy with regards to improvement in motor function for patients with type II and III. Clinical trials are still ongoing and are currently under review in the US, Europe, and the UK for licensing.<xref ref-type="bibr" rid="article-29346.r38">[38]</xref></p>
      </sec>
      <sec id="article-29346.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>If SMA is clinically suspected, but genetic testing fails to identify pathological biallelic versions/absence of SMN1, there are a plethora of extremely rare conditions of varying etiology (usually secondary to a genetic disorder) that can present similarly to SMA but often with distinguishing features not seen in SMA. These are sometimes referred to as non-5q13-associated-SMAs.<xref ref-type="bibr" rid="article-29346.r4">[4]</xref></p>
        <p>A thorough history, examination as well as CK, EMG, nerve conduction studies, muscle biopsy, MRI, as well as referral to a geneticist can all be key to determining the correct diagnosis.<xref ref-type="bibr" rid="article-29346.r25">[25]</xref><xref ref-type="bibr" rid="article-29346.r2">[2]</xref>&#x000a0;A detailed review of differential diagnosis is beyond the scope of this article, but the following list is a brief synopsis of differentials grouped by age as summarised by GeneReviews:<xref ref-type="bibr" rid="article-29346.r2">[2]</xref></p>
        <p>Congenital - &#x0003c;6months: Pompe disease, Prader-Willi syndrome, Myotonic dystrophy type 1, Sellweger spectrum disorder, Congenital myasthenic syndromes, X-linked infantile spinal muscular atrophy. It is essential to consider congenital myopathies, disorders of metabolism, and disorders of mitochondria.</p>
        <p>Childhood: Botulism, hexosaminidase A deficiency, Guillain-Barr&#x000e9;, Duchenne muscular dystrophy, Fazio-Londe syndrome, Hirayama disease</p>
        <p>Adulthood: Amyotrophic lateral sclerosis, spinal, and bulbar muscular atrophy<xref ref-type="bibr" rid="article-29346.r2">[2]</xref><xref ref-type="bibr" rid="article-29346.r4">[4]</xref></p>
      </sec>
      <sec id="article-29346.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Historically prognosis has been dependent on SMA type with type 0 being the worst and individuals dying within the first months of life and type IV having a mild disease that does not affect the life expectancy.<xref ref-type="bibr" rid="article-29346.r3">[3]</xref>&#x000a0;However, with the recent introduction of disease-modifying agents such as onasemnogene abeparvovec, there have already been reported cases of SMA type I patients living longer than the historical cohort data would suggest, prognosis, therefore could potentially be much improved and is the source of ongoing study.<xref ref-type="bibr" rid="article-29346.r39">[39]</xref></p>
      </sec>
      <sec id="article-29346.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Individuals with SMA suffer from respiratory, gastrointestinal, orthopedic complications that affect the quality of life and can potentially be life-threatening, for example, chest infections secondary to aspiration due to inadequate swallowing and muscle weakness.<xref ref-type="bibr" rid="article-29346.r15">[15]</xref> Patients with SMA are prone to suffer from metabolic acidosis, especially during periods of illness or fasting, the underlying etiology of this predisposition is unknown, and there have been suggestions that dysfunctional glucose metabolism secondary to pancreatic abnormalities may play a role.<xref ref-type="bibr" rid="article-29346.r40">[40]</xref></p>
      </sec>
      <sec id="article-29346.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>As with any disease that has a significant genetic component, genetic counseling to patients (if age appropriate) and family members is important for patients and families to make informed decisions. Due to SMA's autosomal recessive inheritance pattern, manner siblings have a 25% chance of being affected, 50% chance of being carriers, and 25% of being unaffected and not being carriers. Ninety-eight percent of parents of an individual with SMA are heterozygote carriers, with the remaining 2% being explained by the de novo pathogenic variant in the child. Preconception counseling should be offered to affected individuals and screening provided for the planned reproductive partner.<xref ref-type="bibr" rid="article-29346.r2">[2]</xref></p>
      </sec>
      <sec id="article-29346.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <list list-type="bullet">
          <list-item>
            <p>SMA results from a homozygous deletion of SMN1 on chromosome 5q13; however, variation in phenotype is usually explainable by the number of SMN2 genes an affected individual possesses.</p>
          </list-item>
          <list-item>
            <p>Historically prognosis for type I has been extremely poor with most [atients dying before their second&#x000a0;birthday; however, novel therapies such as&#x000a0;onasemnogene abeparvovec and&#x000a0;nusinersen are recently licensed medications that are showing promise at prolonging life and reducing morbidity.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29346.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Effective use and co-ordination of care via the utilization of an interprofessional team is required to optimize treatment, treatment planning, and share decision making. Members of an interprofessional team are likely to include but not restricted to: pediatricians, pediatric nurses, neurologists, geneticists, pediatric surgeons, orthotics, orthopedic surgeons, physiotherapists, nutritionists, palliative care specialists, and nurse practitioners.<xref ref-type="bibr" rid="article-29346.r27">[27]</xref><xref ref-type="bibr" rid="article-29346.r39">[39]</xref>&#x000a0;[Level 5]</p>
      </sec>
      <sec id="article-29346.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29346&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29346">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/neurology/spinal-muscle-atrophy/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=29346">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29346/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29346">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-29346.s16">
        <title>References</title>
        <ref id="article-29346.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kolb</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kissel</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Spinal muscular atrophy: a timely review.</article-title>
            <source>Arch Neurol</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>68</volume>
            <issue>8</issue>
            <fpage>979</fpage>
            <page-range>979-84</page-range>
            <pub-id pub-id-type="pmid">21482919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Prior</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Leach</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Finanger</surname>
                <given-names>EL</given-names>
              </name>
            </person-group>
            <chapter-title>Spinal Muscular Atrophy</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2000</year>
            <month>2</month>
            <day>24</day>
            <pub-id pub-id-type="pmid">20301526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D'Amico</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mercuri</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tiziano</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Bertini</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Spinal muscular atrophy.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2011</year>
            <month>Nov</month>
            <day>02</day>
            <volume>6</volume>
            <fpage>71</fpage>
            <pub-id pub-id-type="pmid">22047105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Darras</surname>
                <given-names>BT</given-names>
              </name>
            </person-group>
            <article-title>Spinal muscular atrophies.</article-title>
            <source>Pediatr Clin North Am</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>62</volume>
            <issue>3</issue>
            <fpage>743</fpage>
            <page-range>743-66</page-range>
            <pub-id pub-id-type="pmid">26022173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dubowitz</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Ramblings in the history of spinal muscular atrophy.</article-title>
            <source>Neuromuscul Disord</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>69</fpage>
            <page-range>69-73</page-range>
            <pub-id pub-id-type="pmid">18951794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lefebvre</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>B&#x000fc;rglen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Reboullet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Clermont</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Burlet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Viollet</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Benichou</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cruaud</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Millasseau</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zeviani</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Identification and characterization of a spinal muscular atrophy-determining gene.</article-title>
            <source>Cell</source>
            <year>1995</year>
            <month>Jan</month>
            <day>13</day>
            <volume>80</volume>
            <issue>1</issue>
            <fpage>155</fpage>
            <page-range>155-65</page-range>
            <pub-id pub-id-type="pmid">7813012</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mailman</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Heinz</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Papp</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Snyder</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Sedra</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Wirth</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Burghes</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Prior</surname>
                <given-names>TW</given-names>
              </name>
            </person-group>
            <article-title>Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2.</article-title>
            <source>Genet Med</source>
            <year>2002</year>
            <season>Jan-Feb</season>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>20</fpage>
            <page-range>20-6</page-range>
            <pub-id pub-id-type="pmid">11839954</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prior</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Krainer</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Hua</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Swoboda</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Snyder</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Bridgeman</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Burghes</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Kissel</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>A positive modifier of spinal muscular atrophy in the SMN2 gene.</article-title>
            <source>Am J Hum Genet</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>85</volume>
            <issue>3</issue>
            <fpage>408</fpage>
            <page-range>408-13</page-range>
            <pub-id pub-id-type="pmid">19716110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ludolph</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Wurster</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic advances in SMA.</article-title>
            <source>Curr Opin Neurol</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>777</fpage>
            <page-range>777-781</page-range>
            <pub-id pub-id-type="pmid">31425176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crawford</surname>
                <given-names>TO</given-names>
              </name>
              <name>
                <surname>Pardo</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>The neurobiology of childhood spinal muscular atrophy.</article-title>
            <source>Neurobiol Dis</source>
            <year>1996</year>
            <month>Apr</month>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>97</fpage>
            <page-range>97-110</page-range>
            <pub-id pub-id-type="pmid">9173917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zald&#x000ed;var</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Montejo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Acevedo</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Guerra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vargas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Garofalo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Alvarez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Alvarez</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Hardiman</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Evidence of reduced frequency of spinal muscular atrophy type I in the Cuban population.</article-title>
            <source>Neurology</source>
            <year>2005</year>
            <month>Aug</month>
            <day>23</day>
            <volume>65</volume>
            <issue>4</issue>
            <fpage>636</fpage>
            <page-range>636-8</page-range>
            <pub-id pub-id-type="pmid">16116135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prior</surname>
                <given-names>TW</given-names>
              </name>
            </person-group>
            <article-title>Spinal muscular atrophy: newborn and carrier screening.</article-title>
            <source>Obstet Gynecol Clin North Am</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>23</fpage>
            <page-range>23-36, Table of Contents</page-range>
            <pub-id pub-id-type="pmid">20494255</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kolb</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Battle</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Dreyfuss</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Molecular functions of the SMN complex.</article-title>
            <source>J Child Neurol</source>
            <year>2007</year>
            <month>Aug</month>
            <volume>22</volume>
            <issue>8</issue>
            <fpage>990</fpage>
            <page-range>990-4</page-range>
            <pub-id pub-id-type="pmid">17761654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bowerman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Y&#x000e1;&#x000f1;ez-Mu&#x000f1;oz</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Ning</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>MJA</given-names>
              </name>
              <name>
                <surname>Gillingwater</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Talbot</surname>
                <given-names>K</given-names>
              </name>
              <collab>UK SMA Research Consortium</collab>
            </person-group>
            <article-title>Therapeutic strategies for spinal muscular atrophy: SMN and beyond.</article-title>
            <source>Dis Model Mech</source>
            <year>2017</year>
            <month>Aug</month>
            <day>01</day>
            <volume>10</volume>
            <issue>8</issue>
            <fpage>943</fpage>
            <page-range>943-954</page-range>
            <pub-id pub-id-type="pmid">28768735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kolb</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kissel</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Spinal Muscular Atrophy.</article-title>
            <source>Neurol Clin</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>831</fpage>
            <page-range>831-46</page-range>
            <pub-id pub-id-type="pmid">26515624</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wijngaarde</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Blank</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Stam</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wadman</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>van den Berg</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>van der Pol</surname>
                <given-names>WL</given-names>
              </name>
            </person-group>
            <article-title>Cardiac pathology in spinal muscular atrophy: a systematic review.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2017</year>
            <month>Apr</month>
            <day>11</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>67</fpage>
            <pub-id pub-id-type="pmid">28399889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rudnik-Sch&#x000f6;neborn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goebel</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Schlote</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Molaian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Omran</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ketelsen</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Korinthenberg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wenzel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lauffer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kreiss-Nachtsheim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wirth</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zerres</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Classical infantile spinal muscular atrophy with SMN deficiency causes sensory neuronopathy.</article-title>
            <source>Neurology</source>
            <year>2003</year>
            <month>Mar</month>
            <day>25</day>
            <volume>60</volume>
            <issue>6</issue>
            <fpage>983</fpage>
            <page-range>983-7</page-range>
            <pub-id pub-id-type="pmid">12654964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zerres</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rudnik-Sch&#x000f6;neborn</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications.</article-title>
            <source>Arch Neurol</source>
            <year>1995</year>
            <month>May</month>
            <volume>52</volume>
            <issue>5</issue>
            <fpage>518</fpage>
            <page-range>518-23</page-range>
            <pub-id pub-id-type="pmid">7733848</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>von Gontard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zerres</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Backes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Laufersweiler-Plass</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wendland</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Melchers</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lehmkuhl</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rudnik-Sch&#x000f6;neborn</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Intelligence and cognitive function in children and adolescents with spinal muscular atrophy.</article-title>
            <source>Neuromuscul Disord</source>
            <year>2002</year>
            <month>Feb</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>130</fpage>
            <page-range>130-6</page-range>
            <pub-id pub-id-type="pmid">11738354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dubowitz</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype.</article-title>
            <source>Eur J Paediatr Neurol</source>
            <year>1999</year>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>49</fpage>
            <page-range>49-51</page-range>
            <pub-id pub-id-type="pmid">10700538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnold</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Kassar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kissel</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Spinal muscular atrophy: diagnosis and management in a new therapeutic era.</article-title>
            <source>Muscle Nerve</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>51</volume>
            <issue>2</issue>
            <fpage>157</fpage>
            <page-range>157-67</page-range>
            <pub-id pub-id-type="pmid">25346245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zerres</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rudnik-Sch&#x000f6;neborn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Forrest</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lusakowska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Borkowska</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hausmanowa-Petrusewicz</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients.</article-title>
            <source>J Neurol Sci</source>
            <year>1997</year>
            <month>Feb</month>
            <day>27</day>
            <volume>146</volume>
            <issue>1</issue>
            <fpage>67</fpage>
            <page-range>67-72</page-range>
            <pub-id pub-id-type="pmid">9077498</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Piepers</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>van den Berg</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Brugman</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Scheffer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ruiterkamp-Versteeg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van Engelen</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Faber</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>de Visser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van der Pol</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Wokke</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>A natural history study of late onset spinal muscular atrophy types 3b and 4.</article-title>
            <source>J Neurol</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>255</volume>
            <issue>9</issue>
            <fpage>1400</fpage>
            <page-range>1400-4</page-range>
            <pub-id pub-id-type="pmid">18575920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taylor</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Yazdanpanah</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Staropoli</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carulli</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dobrowolski</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Hannon</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Vogt</surname>
                <given-names>RF</given-names>
              </name>
            </person-group>
            <article-title>Newborn blood spot screening test using multiplexed real-time PCR to simultaneously screen for spinal muscular atrophy and severe combined immunodeficiency.</article-title>
            <source>Clin Chem</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>61</volume>
            <issue>2</issue>
            <fpage>412</fpage>
            <page-range>412-9</page-range>
            <pub-id pub-id-type="pmid">25502182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Han</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and clinical management of spinal muscular atrophy.</article-title>
            <source>Phys Med Rehabil Clin N Am</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>661</fpage>
            <page-range>661-80, xii</page-range>
            <pub-id pub-id-type="pmid">18625423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schroth</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>Special considerations in the respiratory management of spinal muscular atrophy.</article-title>
            <source>Pediatrics</source>
            <year>2009</year>
            <month>May</month>
            <volume>123 Suppl 4</volume>
            <fpage>S245</fpage>
            <page-range>S245-9</page-range>
            <pub-id pub-id-type="pmid">19420154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Finkel</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Bertini</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Schroth</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Simonds</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aloysius</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Main</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Crawford</surname>
                <given-names>TO</given-names>
              </name>
              <name>
                <surname>Trela</surname>
                <given-names>A</given-names>
              </name>
              <collab>Participants of the International Conference on SMA Standard of Care</collab>
            </person-group>
            <article-title>Consensus statement for standard of care in spinal muscular atrophy.</article-title>
            <source>J Child Neurol</source>
            <year>2007</year>
            <month>Aug</month>
            <volume>22</volume>
            <issue>8</issue>
            <fpage>1027</fpage>
            <page-range>1027-49</page-range>
            <pub-id pub-id-type="pmid">17761659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Durkin</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Schroth</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Helin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shaaban</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>Early laparoscopic fundoplication and gastrostomy in infants with spinal muscular atrophy type I.</article-title>
            <source>J Pediatr Surg</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>43</volume>
            <issue>11</issue>
            <fpage>2031</fpage>
            <page-range>2031-7</page-range>
            <pub-id pub-id-type="pmid">18970936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sproule</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Montes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Battista</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Koenigsberger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Punyanitya</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>De Vivo</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Kaufmann</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Increased fat mass and high incidence of overweight despite low body mass index in patients with spinal muscular atrophy.</article-title>
            <source>Neuromuscul Disord</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>391</fpage>
            <page-range>391-6</page-range>
            <pub-id pub-id-type="pmid">19427208</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davis</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Godshall</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Seffrood</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>LaSalle</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schroth</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Swoboda</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Nutritional practices at a glance: spinal muscular atrophy type I nutrition survey findings.</article-title>
            <source>J Child Neurol</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>29</volume>
            <issue>11</issue>
            <fpage>1467</fpage>
            <page-range>1467-72</page-range>
            <pub-id pub-id-type="pmid">24097849</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haaker</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fujak</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Proximal spinal muscular atrophy: current orthopedic perspective.</article-title>
            <source>Appl Clin Genet</source>
            <year>2013</year>
            <month>Nov</month>
            <day>14</day>
            <volume>6</volume>
            <issue>11</issue>
            <fpage>113</fpage>
            <page-range>113-20</page-range>
            <pub-id pub-id-type="pmid">24399883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Claborn</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Gildon</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Nusinersen: A Treatment for Spinal Muscular Atrophy.</article-title>
            <source>Ann Pharmacother</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>53</volume>
            <issue>1</issue>
            <fpage>61</fpage>
            <page-range>61-69</page-range>
            <pub-id pub-id-type="pmid">30008228</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Finkel</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Mercuri</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Darras</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Connolly</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kuntz</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Kirschner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chiriboga</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Servais</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tizzano</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Topaloglu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tulinius</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Montes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Glanzman</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bishop</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>ZJ</given-names>
              </name>
              <name>
                <surname>Gheuens</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Farwell</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>De Vivo</surname>
                <given-names>DC</given-names>
              </name>
              <collab>ENDEAR Study Group</collab>
            </person-group>
            <article-title>Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>Nov</month>
            <day>02</day>
            <volume>377</volume>
            <issue>18</issue>
            <fpage>1723</fpage>
            <page-range>1723-1732</page-range>
            <pub-id pub-id-type="pmid">29091570</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malone</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Dean</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Arjunji</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cyr</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Maru</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sproule</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Feltner</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Dabbous</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients.</article-title>
            <source>J Mark Access Health Policy</source>
            <year>2019</year>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>1601484</fpage>
            <pub-id pub-id-type="pmid">31105909</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mendell</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Al-Zaidy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Rodino-Klapac</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Prior</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Lowes</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Alfano</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Church</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kissel</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Nagendran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>L'Italien</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sproule</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cardenas</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Heitzer</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Kaspar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Corcoran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Likhite</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miranda</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Foust</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Burghes</surname>
                <given-names>AHM</given-names>
              </name>
              <name>
                <surname>Kaspar</surname>
                <given-names>BK</given-names>
              </name>
            </person-group>
            <article-title>Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>Nov</month>
            <day>02</day>
            <volume>377</volume>
            <issue>18</issue>
            <fpage>1713</fpage>
            <page-range>1713-1722</page-range>
            <pub-id pub-id-type="pmid">29091557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahajan</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Onasemnogene Abeparvovec for Spinal Muscular Atrophy: The Costlier Drug Ever.</article-title>
            <source>Int J Appl Basic Med Res</source>
            <year>2019</year>
            <season>Jul-Sep</season>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>127</fpage>
            <page-range>127-128</page-range>
            <pub-id pub-id-type="pmid">31392173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoy</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Onasemnogene Abeparvovec: First Global Approval.</article-title>
            <source>Drugs</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>79</volume>
            <issue>11</issue>
            <fpage>1255</fpage>
            <page-range>1255-1262</page-range>
            <pub-id pub-id-type="pmid">31270752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ratni</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ebeling</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baird</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bendels</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bylund</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Denk</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Guerard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jablonski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Khwaja</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kletzl</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Kustermann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Marquet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Metzger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Naryshkin</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Paushkin</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Pinard</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Poirier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reutlinger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weetall</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zeller</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA).</article-title>
            <source>J Med Chem</source>
            <year>2018</year>
            <month>Aug</month>
            <day>09</day>
            <volume>61</volume>
            <issue>15</issue>
            <fpage>6501</fpage>
            <page-range>6501-6517</page-range>
            <pub-id pub-id-type="pmid">30044619</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>TH</given-names>
              </name>
            </person-group>
            <article-title>New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?</article-title>
            <source>Int J Mol Sci</source>
            <year>2020</year>
            <month>May</month>
            <day>07</day>
            <volume>21</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">32392694</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29346.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bowerman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Swoboda</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Michalski</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Reeks</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Beauvais</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Woulfe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Screaton</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Kothary</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Glucose metabolism and pancreatic defects in spinal muscular atrophy.</article-title>
            <source>Ann Neurol</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>72</volume>
            <issue>2</issue>
            <fpage>256</fpage>
            <page-range>256-68</page-range>
            <pub-id pub-id-type="pmid">22926856</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
